ATE248594T1 - Irbesartanhaltiges arzneimittel - Google Patents

Irbesartanhaltiges arzneimittel

Info

Publication number
ATE248594T1
ATE248594T1 AT96304291T AT96304291T ATE248594T1 AT E248594 T1 ATE248594 T1 AT E248594T1 AT 96304291 T AT96304291 T AT 96304291T AT 96304291 T AT96304291 T AT 96304291T AT E248594 T1 ATE248594 T1 AT E248594T1
Authority
AT
Austria
Prior art keywords
irbesart
product containing
medicinal product
medicinal
product
Prior art date
Application number
AT96304291T
Other languages
English (en)
Inventor
Cathy C Ku
Omar L Sprockel
Beth A Rubitski
Divyakant S Desai
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23876256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE248594(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of ATE248594T1 publication Critical patent/ATE248594T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
AT96304291T 1995-06-07 1996-06-07 Irbesartanhaltiges arzneimittel ATE248594T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47261895A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ATE248594T1 true ATE248594T1 (de) 2003-09-15

Family

ID=23876256

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96304291T ATE248594T1 (de) 1995-06-07 1996-06-07 Irbesartanhaltiges arzneimittel
AT02016237T ATE503478T1 (de) 1995-06-07 1996-06-07 Arzneizubereitung enthaltend irbesartan und ein diuretikum

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02016237T ATE503478T1 (de) 1995-06-07 1996-06-07 Arzneizubereitung enthaltend irbesartan und ein diuretikum

Country Status (23)

Country Link
EP (2) EP0747050B2 (de)
JP (1) JP3162626B2 (de)
KR (1) KR100442719B1 (de)
CN (1) CN1149083C (de)
AR (2) AR002350A1 (de)
AT (2) ATE248594T1 (de)
AU (1) AU702651B2 (de)
CA (1) CA2177772C (de)
CZ (1) CZ291532B6 (de)
DE (2) DE69638348D1 (de)
DK (2) DK1275391T3 (de)
ES (2) ES2205000T5 (de)
HK (1) HK1002384A1 (de)
HU (1) HU229369B1 (de)
IL (1) IL118309A (de)
NO (2) NO310495B1 (de)
NZ (2) NZ329547A (de)
PL (1) PL184893B1 (de)
PT (2) PT1275391E (de)
RU (2) RU2210368C1 (de)
SG (1) SG49956A1 (de)
TW (1) TW442301B (de)
ZA (1) ZA964337B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU763309B2 (en) * 1998-07-20 2003-07-17 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
JP4565456B2 (ja) * 1999-11-02 2010-10-20 塩野義製薬株式会社 着色顆粒の色素定着法
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
DE10244681A1 (de) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
JP2009513543A (ja) * 2003-07-16 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング クロルタリドンの組み合わせ
TR200301553A1 (tr) * 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
JP2005126338A (ja) * 2003-10-21 2005-05-19 Boehringer Ingelheim Pharma Gmbh & Co Kg 心不全治療剤
WO2005089720A1 (en) * 2004-03-10 2005-09-29 Ranbaxy Laboratories Limited Valsartan tablets and the process for the preparation thereof
PL1750862T3 (pl) * 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
WO2006013545A1 (en) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Pharmaceutical compositions of irbesartan
PT1928409E (pt) 2005-09-12 2012-11-27 Actelion Pharmaceuticals Ltd Composição farmacêutica estável que compreende uma pirimidina-sulfamida
RU2469709C2 (ru) * 2005-11-17 2012-12-20 Новартис Аг Фармацевтическая композиция
EP1806130B1 (de) * 2006-01-09 2010-03-31 KRKA, D.D., Novo Mesto Irbesartan enthaltende feste Zubereitung
DE102006006588A1 (de) * 2006-02-13 2007-08-16 Ratiopharm Gmbh Schnell freisetzende Irbesartan-haltige pharmazeutische Zusammensetzung
NZ573566A (en) 2006-06-12 2012-01-12 Schering Corp Pharmaceutical formulations and compositions of a selective antagonist of either cxcr2 or both cxcr1 and cxcr2 and methods of using the same for treating inflammatory disorders
ES2523729T3 (es) 2006-06-16 2014-12-01 Lek Pharmaceuticals D.D. Composición farmacéutica que comprende hidroclorotiazida y telmisartán
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP1923053A1 (de) * 2006-09-27 2008-05-21 Novartis AG Pharmazeutische Zusammensetzung umfassend Nilotinib oder dessen Salz
WO2008125388A1 (en) * 2007-04-17 2008-10-23 Ratiopharm Gmbh Pharmaceutical compositions comprising irbesartan
JP5683058B2 (ja) * 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
PT2065035E (pt) 2007-11-28 2010-10-04 Lesvi Laboratorios Sl Formulações farmacêuticas contendo irbesartan
CN101327213B (zh) * 2008-06-20 2010-10-13 海南锦瑞制药股份有限公司 厄贝沙坦氢氯噻嗪药用组合物及其制备方法
JP5296456B2 (ja) * 2008-08-26 2013-09-25 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
AU2009349125B2 (en) * 2009-06-30 2016-05-19 Sanofi Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
WO2011010316A1 (en) * 2009-07-20 2011-01-27 Hetero Research Foundation Pharmaceutical compositions of irbesartan
CN103893140B (zh) * 2009-11-09 2016-06-01 惠氏有限责任公司 来那替尼马来酸盐的片剂制剂
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
JP4974255B2 (ja) * 2010-03-16 2012-07-11 塩野義製薬株式会社 アンジオテンシンｉｉ受容体拮抗剤の配合剤
JP5459670B2 (ja) * 2010-05-07 2014-04-02 塩野義製薬株式会社 着色顆粒の色素定着化剤
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
EA201390079A1 (ru) * 2010-07-08 2013-09-30 Рациофарм Гмбх Пероральная лекарственная форма деферазирокса
WO2013100112A1 (ja) * 2011-12-28 2013-07-04 ニプロ株式会社 アンギオテンシンｉｉ拮抗作用を有する化合物を含有する固形医薬組成物
PL2851075T3 (pl) 2012-05-14 2022-02-21 Shionogi & Co., Ltd. Preparat zawierający pochodną 6,7-nienasyconego-7-karbamoilomorfinanu
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
JP5714652B2 (ja) * 2013-06-13 2015-05-07 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP6238921B2 (ja) * 2014-02-17 2017-11-29 大原薬品工業株式会社 イルベサルタンを含有する錠剤
JP5978335B2 (ja) * 2015-03-11 2016-08-24 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP6199922B2 (ja) * 2015-03-20 2017-09-20 大原薬品工業株式会社 化学的な安定性が向上したイルベサルタン含有錠剤
JP6445923B2 (ja) * 2015-04-22 2018-12-26 ダイト株式会社 イルベサルタン含有錠剤の調製方法
JP6737060B2 (ja) * 2015-09-11 2020-08-05 ニプロ株式会社 イルベサルタンを含有する医薬組成物の製造方法
JP6151413B2 (ja) * 2016-07-25 2017-06-21 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP2017141299A (ja) * 2017-05-24 2017-08-17 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP6233911B2 (ja) * 2017-08-22 2017-11-22 大原薬品工業株式会社 化学的な安定性が向上したイルベサルタン含有錠剤
JP2018009032A (ja) * 2017-10-19 2018-01-18 大原薬品工業株式会社 化学的な安定性が向上したイルベサルタン含有錠剤
CN108434112A (zh) * 2018-06-08 2018-08-24 华益药业科技(安徽)有限公司 一种厄贝沙坦片及其制备方法
JP2018168185A (ja) * 2018-07-05 2018-11-01 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
PH12018000390A1 (en) * 2018-11-20 2020-09-28 Novex Science Pte Ltd Carbocysteine and zinc tablet
JP2019203031A (ja) * 2019-09-06 2019-11-28 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
GR1010320B (el) * 2021-08-04 2022-10-11 Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3744317C1 (de) 1987-12-28 1989-05-24 Rudolf Dr Rer Nat Kuerner Verwendung von Calciumsulfat zur Verbesserung der Fermentierung organischer Abfallstoffe
EP0400835A1 (de) 1989-05-15 1990-12-05 Merck & Co. Inc. Substituierte Benzimidazole als Angiotensin II-Hemmer
US5164407A (en) 1989-07-03 1992-11-17 Merck & Co., Inc. Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
IE910913A1 (en) * 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
IL99372A0 (en) * 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
IS1756B (is) 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
EP0502575A1 (de) 1991-03-06 1992-09-09 Merck & Co. Inc. Substituierte 1-(2H)-Isoquinolinone
WO1994009778A1 (en) 1992-10-26 1994-05-11 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
EP0629408A1 (de) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Kombination von Angiotensin-Converting-Enzyme Hemmern mit A-II-Antagonisten
US5541209A (en) * 1994-08-22 1996-07-30 Bristol-Myers Squibb Company Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative
FR2725987B1 (fr) * 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive

Also Published As

Publication number Publication date
DK0747050T4 (da) 2013-05-21
HK1002384A1 (en) 1998-08-21
CA2177772C (en) 2007-04-10
NZ286612A (en) 1998-03-25
DE69629755D1 (de) 2003-10-09
JPH08333253A (ja) 1996-12-17
NO962387D0 (no) 1996-06-06
DE69629755T2 (de) 2004-07-01
DK0747050T3 (da) 2003-12-15
NO310393B1 (no) 2001-07-02
HUP9601564A2 (hu) 1998-09-28
JP3162626B2 (ja) 2001-05-08
CN1149083C (zh) 2004-05-12
DE69638348D1 (de) 2011-05-12
KR970000232A (ko) 1997-01-21
RU2001130903A (ru) 2004-02-27
CN1144656A (zh) 1997-03-12
HUP9601564A3 (en) 2000-12-28
PL314670A1 (en) 1996-12-09
KR100442719B1 (ko) 2004-10-08
AU702651B2 (en) 1999-02-25
ES2205000T3 (es) 2004-05-01
EP1275391A1 (de) 2003-01-15
IL118309A (en) 2003-06-24
AU5476396A (en) 1996-12-19
HU9601564D0 (en) 1996-08-28
NZ329547A (en) 1998-06-26
MX9602103A (es) 1997-09-30
RU2210368C1 (ru) 2003-08-20
DE69629755T3 (de) 2013-08-08
EP0747050B2 (de) 2013-02-13
IL118309A0 (en) 1996-09-12
CA2177772A1 (en) 1996-12-08
ATE503478T1 (de) 2011-04-15
HU229369B1 (en) 2013-11-28
SG49956A1 (en) 1998-06-15
ES2205000T5 (es) 2013-05-30
TW442301B (en) 2001-06-23
ES2363127T3 (es) 2011-07-21
AR002350A1 (es) 1998-03-11
EP0747050A1 (de) 1996-12-11
PT1275391E (pt) 2011-06-30
EP0747050B1 (de) 2003-09-03
CZ291532B6 (cs) 2003-03-12
NO962387L (no) 1996-12-09
NO20004743D0 (no) 2000-09-22
CZ163496A3 (en) 1996-12-11
PT747050E (pt) 2003-12-31
PL184893B1 (pl) 2003-01-31
DK1275391T3 (da) 2011-07-11
NO310495B1 (no) 2001-07-16
NO20004743L (no) 1996-12-09
EP1275391B1 (de) 2011-03-30
ZA964337B (en) 1997-11-28
AR054782A2 (es) 2007-07-18
RU2181590C2 (ru) 2002-04-27

Similar Documents

Publication Publication Date Title
ATE248594T1 (de) Irbesartanhaltiges arzneimittel
FI954402A (fi) Uusi farmaseuttinen tuote
DE69513671D1 (de) Arzneimittel
BR9610153A (pt) Formulações farmacêuticas
BR9611626A (pt) Formulações farmacéuticas
FI932655A (fi) Imidatderivat av farmaceutiskt anvaendbara antikonvulsiva sulfamat
NO20004345D0 (no) Farmasøytisk sammensetning
NO981008D0 (no) Farmasöytisk formulering
BR9610214A (pt) Compostos farmacéuticos
ATE229801T1 (de) Arzneimittel bestehend aus diclofenac
DK0813586T3 (da) Mugfjernelsesprodukt
DE29513226U1 (de) Tablettenspender
LV11727A (lv) Farmaceitiska kompozicija
DK86492D0 (da) Laegemiddel
FI973280A0 (fi) Farmaseuttinen koostumus
FI973230A (fi) Uusi farmaseuttinen formulaatio
BR9603088A (pt) Produto embalado
DE59610423D1 (de) Partikulare arzneiform
NO965448L (no) Farmasöytiske forbindelser
BR9605777A (pt) Composição farmacêutica
BR9605131A (pt) Composição farmacêutica
UA1090S (uk) Фармацевтичний виріб
DE69819203D1 (de) Trinkbares arzneimittel
UA25976C2 (uk) Противиразковий лікарський препарат
DE29502489U1 (de) Heilpackung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0747050

Country of ref document: EP